Developing a protein subunit vaccine for COVID-19

“...we believe that the platform that we have developed ... can be adapted to develop a pan-coronavirus vaccine, provided we can develop the right antigen design.”

Supplied to the Indian government at $2 per dose, the recombinant protein subunit vaccine Corbevax has been administered to 100 million people. This article will discuss the rationale behind the choice of platform, immunogen, and adjuvants.

Please enter your email to access content Read now